Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23862469 | 0.72 | HTR6 (0.40) | TRPV1TRPV4MAPK1ALDH1A1PPARG | |
| SCHEMBL21577671 | 0.68 | MAPT (0.36) | KMT2ATSHRALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL19177266 | 0.68 | KDM4E (0.46) | KMT2AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL3439599 | 0.67 | MAPT (0.57) | KMT2ATSHRALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL8014420 | 0.66 | ESR1 (0.40) | TRPV1TRPV4PPARGPPARA | |
| SCHEMBL20439222 | 0.65 | KDM4E (0.40) | KMT2APKMALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL8015012 | 0.65 | PPARD (0.39) | TRPV1TRPV4PPARGPPARA | |
| SCHEMBL8037397 | 0.64 | PPARD (0.57) | PPARGPPARA | |
| SCHEMBL7037211 | 0.62 | ESR1 (0.37) | TRPV1TRPV4PPARGPPARA | |
| SCHEMBL21895251 | 0.62 | KDM4E (0.48) | KMT2AALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202354-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180022707-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022707-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM1B, KDM6B, KDM2B | TRPV1 3727/4885TRPV4 4269/4885KMT2A 29/4885 |
| US-10202354-B2 | Therapeutic compounds and uses thereof | KDM1B, KDM6B, KDM2B | TRPV1 3727/4885TRPV4 4269/4885KMT2A 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.